Eli Lilly and Company $LLY Stock Purchased by Woodstock Corp

Key Points

• Woodstock Corp increased its Eli Lilly position by 15.5% in the third quarter, bringing its holdings to 13,763 shares valued at approximately $15.9 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with earnings of $8.38 per share and revenue of $22.97 billion, surpassing analyst estimates and marking 47.7% year-over-year revenue growth.
• The stock traded near $1,183.51, while analysts maintained a broadly positive outlook with a “Moderate Buy” consensus and an average price target of $1,313.43; however, insiders have sold $15.96 million worth of shares over the past 90 days.

Woodstock Corp raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,763 shares of the company's stock after acquiring an additional 1,846 shares during the quarter. Eli Lilly and Company makes up about 1.3% of Woodstock Corp's holdings, making the stock its 21st biggest holding. Woodstock Corp's holdings in Eli Lilly and Company were worth $15,925,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the fourth quarter valued at $30,000. Maseco LLP raised its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $39,000. Finally, Aventus Investment Advisors Inc. lifted its holdings in Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly and Company stock opened at $1,183.51 on Tuesday. The company has a market capitalization of $1.11 trillion, a P/E ratio of 39.72, a PEG ratio of 1.47 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65. The stock has a 50-day simple moving average of $1,175.57 and a 200-day simple moving average of $1,100.31.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the company posted $6.31 earnings per share. The firm's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 36.19 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts expect Eli Lilly to generate as much as $87 billion in 2026 revenue, driven by Zepbound, diabetes treatments, and its expanding obesity-drug portfolio. The company’s pipeline, including next-generation weight-loss candidates, strengthens the long-term growth outlook. Eli Lilly Expects Up to $87 Billion in 2026 Revenue
• Positive Sentiment: Royal Bank of Canada reiterated its Outperform rating and set a $1,500 price target, implying substantial upside from the reference price. Wall Street’s overall rating remains “Moderate Buy.” Eli Lilly Outperform Rating Reiterated
• Positive Sentiment: Phase 3b data for Taltz combined with Zepbound showed stronger skin-clearance and weight-loss results than standard treatment, potentially expanding Lilly’s cardiometabolic opportunity. Eli Lilly Phase 3b Win
• Neutral Sentiment: A potential stock split is receiving attention because LLY trades above $1,000, but management has not announced one; a split would not change the company’s underlying value. Will Eli Lilly Do a Stock Split
• Negative Sentiment: A drug combination produced more weight loss than Zepbound alone, but discontinuation rates were considerably higher. That raises questions about tolerability, adherence, and the commercial potential of the regimen. Drug Combination Generated More Weight Loss
• Negative Sentiment: LLY’s recent pullback reflects profit-taking after a major rally, while its high valuation leaves the shares sensitive to any slowdown in obesity-drug growth or disappointing clinical data. Eli Lilly Stock Has Pulled Back

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. HSBC upped their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research report on Thursday, September 10th. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research note on Friday, September 18th. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. Finally, The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a "buy" rating in a research note on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.